NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $4.99 payment

Ace your North American Pharmacist Licensure Examination (NAPLEX) with our comprehensive practice test. Features include interactive flashcards, multiple-choice questions, with detailed hints and explanations. Fast-track your pharmacy career today!

Practice this question and more.

What is a treatment option for hormone-sensitive breast cancer in premenopausal women?

Tamoxifen
Aromatase Inhibitor
Raloxifene
Fulvestrant

The correct answer is: Tamoxifen

Tamoxifen is a treatment option for hormone-sensitive breast cancer in premenopausal women because it is a selective estrogen receptor modulator (SERM) that blocks the effects of estrogen in the breast tissue. In premenopausal women, the ovaries are still producing estrogen, and tamoxifen helps to block the estrogen receptors on the breast cancer cells, stopping the cancer cells from receiving the hormone they need to grow. Aromatase inhibitors, on the other hand, are more suitable for postmenopausal women because they interfere with the production of estrogen in peripheral tissues. Raloxifene is also a SERM, but it is not typically used as a first-line treatment for hormone-sensitive breast cancer. Fulvestrant is a selective estrogen receptor degrader (SERD) and is generally used in postmenopausal women with hormone receptor-positive metastatic breast cancer.